Novogen Limited (NASDAQ: NVGN) is a public, Australian-US drug development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University. Novogen has two drug technology platforms yielding drug candidates that are first-in-class with potential application across a broad range of degenerative diseases. In the oncology field, the ultimate objective is to see both drug technologies used in combination as first-line therapy across most forms of cancer, with the objective of preventing tumor recurrence, according to the company’s website and news releases (see “About Novogen” section: http://www.novogen.com/pdf/150605_TRXE-009_Crosses_BBB.pdf).
SNNLive spoke with Dr. Graham Kelly, Chairman and CEO of Novogen Limited at the Marcum MicroCap Conference 2015 in New York City, NY.
“Novogen is a biotech company, more specifically we’re a drug discovery and drug development [company]. We’re pre-clinical; we’re about 6 months away from having our first test product into the clinic.,” Dr. Kelly begins.
He continues by discussing how the company is developing its two drug technology platforms, as well as describes CanTx Inc, their joint venture company with Yale University.
Dr. Kelly concludes with his background and how the FDA treats companies, “if there’s an experimental drug that’s showing good evidence of clinical benefit in it’s early stages, then the FDA is keen to have a talk to companies to see if they what they can do to expedite getting that drug into the market because people are dying everyday from this terrible disease…we hope and we expect that this first drug will show some clear clinical benefit, in which case we would hope that it could go through that accelerated system.”
For more information about Novogen Limited, go to: www.Novogen.com
© 2017 Stock News Now
Supported by Superior Web Solutions